Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2002 1
2007 1
2008 1
2011 1
2014 1
2015 2
2016 2
2020 6
2021 9
2022 6
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes.
Hallakou-Bozec S, Vial G, Kergoat M, Fouqueray P, Bolze S, Borel AL, Fontaine E, Moller DE. Hallakou-Bozec S, et al. Among authors: bolze s. Diabetes Obes Metab. 2021 Mar;23(3):664-673. doi: 10.1111/dom.14277. Epub 2020 Dec 29. Diabetes Obes Metab. 2021. PMID: 33269554 Free PMC article. Review.
Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model.
Vial G, Chauvin MA, Bendridi N, Durand A, Meugnier E, Madec AM, Bernoud-Hubac N, Pais de Barros JP, Fontaine É, Acquaviva C, Hallakou-Bozec S, Bolze S, Vidal H, Rieusset J. Vial G, et al. Among authors: bolze s. Diabetes. 2015 Jun;64(6):2254-64. doi: 10.2337/db14-1220. Epub 2014 Dec 31. Diabetes. 2015. PMID: 25552598
Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin.
Theurey P, Vial G, Fontaine E, Monternier PA, Fouqueray P, Bolze S, Moller DE, Hallakou-Bozec S. Theurey P, et al. Among authors: bolze s. Physiol Rep. 2022 Mar;10(5):e15151. doi: 10.14814/phy2.15151. Physiol Rep. 2022. PMID: 35274817 Free PMC article.
Imeglimin: A Clinical Pharmacology Review.
Chevalier C, Fouqueray P, Bolze S. Chevalier C, et al. Among authors: bolze s. Clin Pharmacokinet. 2023 Sep 15. doi: 10.1007/s40262-023-01301-y. Online ahead of print. Clin Pharmacokinet. 2023. PMID: 37713097 Review.
Imeglimin preserves islet β-cell mass in Type 2 diabetic ZDF rats.
Hallakou-Bozec S, Kergoat M, Moller DE, Bolze S. Hallakou-Bozec S, et al. Among authors: bolze s. Endocrinol Diabetes Metab. 2020 Nov 7;4(2):e00193. doi: 10.1002/edm2.193. eCollection 2021 Apr. Endocrinol Diabetes Metab. 2020. PMID: 33855202 Free PMC article.
Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis.
Gluais-Dagorn P, Foretz M, Steinberg GR, Batchuluun B, Zawistowska-Deniziak A, Lambooij JM, Guigas B, Carling D, Monternier PA, Moller DE, Bolze S, Hallakou-Bozec S. Gluais-Dagorn P, et al. Among authors: bolze s. Hepatol Commun. 2022 Jan;6(1):101-119. doi: 10.1002/hep4.1799. Epub 2021 Sep 7. Hepatol Commun. 2022. PMID: 34494384 Free PMC article.
28 results